Dr. Reddy's Laboratories logo

Dr. Reddy's Laboratories results

NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap

Last close ₹1,229.50down ₹9.50 (0.77%)BSE ₹1,224.50

Share price at the NSE close on 23 Oct 2026. Previous close ₹1,239.00.

52-week range of traded prices to 23 Oct 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
Market cap
₹1,02,624 Cr104th largest listed
P/E
31.8
P/B
2.7
Dividend yield
0.65%
ROE
9.0%
ROCE
6.8%
Debt to equity
0.16
Volume, NSE
15,50,20651.1% delivered

Q2 results, quarter to Sep 2026

Consolidated: the company and its subsidiaries together. ₹ crore.Dr. Reddy's Laboratories annual results and balance sheet

Revenue
₹8,698 Cr−1.5% on a year ago · +7.4% on the quarter before
Operating profit
₹1,731 Cr−13.9% on a year ago · +101.3% on the quarter before
Net profit
₹913 Cr−31.7% on a year ago · +109.6% on the quarter before
Earnings per share
₹11.10−31.4% on a year ago · +108.3% on the quarter before
Operating margin
19.9%
Net margin
10.5%

From revenue to net profit, ₹ crore

  1. Revenue8,698
  2. Materials and goods−3,168
  3. Employee costs−1,612
  4. Other expenses−2,187
  5. Operating profit1,731
  6. Depreciation−527
  7. Other income+156
  8. Finance costs−125
  9. Profit before tax1,235
  10. Tax−314
  11. Joint ventures−7.7
  12. Net profit913

Dr. Reddy's Laboratories results by quarter

Consolidated: the company and its subsidiaries together. Latest quarter to Sep 2026. Results for the quarter to Dec 2026 are due by 14 Feb 2027, 45 days after it ends.Results filings and date

Revenue and net profit by quarter, ₹ crore

  • Revenue
  • Net profit

Operating and net margin by quarter, per cent

  • Operating margin
  • Net margin
₹ croreDec 2021Q3Filed 28 JanMar 2022Q4Filed 19 MayJun 2022Q1Filed 29 JulSep 2022Q2Filed 29 OctDec 2022Q3Filed 25 JanMar 2023Q4Filed 12 MayJun 2023Q1Filed 26 JulSep 2023Q2Filed 28 OctDec 2023Q3Filed 31 JanMar 2024Q4Filed 8 MayJun 2024Q1Filed 30 JulSep 2024Q2Filed 5 NovDec 2024Q3Filed 24 JanMar 2025Q4Filed 10 JunJun 2025Q1Filed 23 JulSep 2025Q2Filed 24 OctDec 2025Q3Filed 21 JanMar 2026Q4Filed 12 MayJun 2026Q1Filed 22 JulSep 2026Q2Filed 23 Oct
Revenue from operations5,3385,4755,2336,3326,7906,3156,7586,9037,2377,1147,6968,0388,3818,5288,5728,8288,7537,5468,1008,698
4,1235,0244,2924,4334,8514,7814,6964,8945,2145,2835,5665,9626,1086,5316,3996,8186,8667,1647,2406,967
Materials and goods bought1,8151,8981,9111,8472,0011,8981,9382,0032,1762,0922,1822,3672,5822,8502,8083,1243,0953,2133,3853,168
Employee costs9569731,0461,1521,1731,2761,1901,2801,2761,2841,4141,3991,3671,4011,5041,4521,5891,4471,6521,612
Other expenses1,3522,1541,3351,4341,6771,6071,5691,6111,7611,9071,9712,1962,1602,2802,0882,2432,1822,5042,2032,187
Operating profit before depreciation1,2164519411,8991,9391,5342,0622,0082,0231,8312,1302,0772,2731,9982,1742,0101,8883838601,731
Operating margin22.8%8.2%18.0%30.0%28.6%24.3%30.5%29.1%28.0%25.7%27.7%25.8%27.1%23.4%25.4%22.8%21.6%5.1%10.6%19.9%
Depreciation and amortisation294293302309324316353376374368381397471455476505521557537527
Other income561228544159139174315216198187308150522290324269475355156
Finance costs2232353142353735395960768266839194106126125
One-off items00000000000000000000
Profit before tax9562481,4591,6001,6321,3221,8461,9131,8261,6021,8771,9111,8702,0001,9051,7391,5411955531,235
265162279499394369445435448295490576470419495408354−22118314
Tax rate27.7%65.2%19.1%31.2%24.1%27.9%24.1%22.7%24.5%18.4%26.1%30.1%25.1%20.9%26.0%23.5%22.9%−11.1%21.3%25.5%
Share of profit of joint ventures and associates1911914684434664606251−8
709971,1891,1141,2449601,4051,4821,3811,3101,3921,3421,4041,5871,4101,3371,190221436913
Other comprehensive income−124−50−213−62170934−11399−562296−2021092051121772461554
Total comprehensive income586479761,0521,4141,0531,4091,3691,4801,2541,3941,6381,2021,6961,6151,4491,367467591917
Net margin13.3%1.8%22.7%17.6%18.3%15.2%20.8%21.5%19.1%18.4%18.1%16.7%16.8%18.6%16.4%15.1%13.6%2.9%5.4%10.5%
Net margin without joint ventures and associates12.9%1.6%22.5%17.4%18.2%15.1%20.7%21.4%19.0%18.4%18.0%16.6%16.7%18.5%16.4%15.1%13.6%2.9%5.4%10.6%
Earnings per share₹8.55₹1.17₹14.33₹13.43₹14.98₹11.56₹16.91₹17.82₹16.59₹15.73₹16.72₹15.08₹16.97₹19.12₹17.04₹16.18₹14.53₹2.65₹5.33₹11.10
Diluted earnings per share₹8.53₹1.17₹14.30₹13.40₹14.95₹11.54₹16.87₹17.78₹16.56₹15.71₹16.70₹15.05₹16.94₹19.10₹17.02₹16.17₹14.52₹2.65₹5.33₹11.09
Earnings per share in rupees, restated for later splits and bonuses.

Filed results, as an XML file each

16 earlier filings

Segment results by quarter

Consolidated, ₹ crore, quarters to Jun 2026.Dr. Reddy's Laboratories segment results by year

  • Global Generics

    Revenue, ₹ crore
    Profit, ₹ crore
  • Pharmaceutical Services and Active Ingredients

    Revenue, ₹ crore
    Profit, ₹ crore
  • Others

    Revenue, ₹ crore
    Profit, ₹ crore
₹ croreSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue of all businesses7,1447,4927,4457,9618,3018,5818,7408,7259,0428,9197,7428,301
Company revenue, as in its results6,9037,2377,1147,6968,0388,3818,5288,5728,8288,7537,5468,100
Revenue6,1136,3126,1296,8937,1647,3817,5437,5737,8247,9576,5937,208
Revenue growth9.1%6.5%12.9%14.6%17.2%16.9%23.1%9.9%9.2%7.8%−12.6%−4.8%
Profit3,8873,9083,7944,4524,5164,5224,4714,6094,6434,5413,1773,713
Profit growth6.3%2.2%13.3%16.0%16.2%15.7%17.8%3.5%2.8%0.4%−28.9%−19.4%
Margin63.6%61.9%61.9%64.6%63.0%61.3%59.3%60.9%59.3%57.1%48.2%51.5%
Revenue9631,0581,1731,0471,1191,0391,1829871,2089471,1251,073
Revenue6812214321181611516410152419
Profit is before tax and finance costs, the way companies report their segments.